Cancer Research UK spinout Achilles raises $175.5m in IPOUK biotech Achilles Therapeutics has completed its initial public offering (IPO) in the US, raising $175.5 million that Share XCancer Research UK spinout Achilles raises $175.5m in IPOhttps://pharmaphorum.com/news/cancer-research-uk-spinout-achilles-raises-175-5m-in-ipo/
9th PREDiCT: Tumor Models Cell Therapy SummitWith high stakes to satisfy unmet patient needs, cell therapy is a promising but challenging field of oncology. Share X9th PREDiCT: Tumor Models Cell Therapy Summithttps://pharmaphorum.com/events/9th-predict-tumor-models-cell-therapy-summit/
FDA fast tracks type 1 diabetes cell therapy from VertexVertex Pharma has made its name with treatment for cystic fibrosis, but has big plans in cell and Share XFDA fast tracks type 1 diabetes cell therapy from Vertexhttps://pharmaphorum.com/news/vertex-claims-fda-fast-track-status-for-diabetes-cell-therapy/
Lymphoma Action – championing the patient voice in cell therapyLymphoma Action is the only UK health charity dedicated to people affected by lymphoma. Chief Executive Ropinder Gill Share XLymphoma Action – championing the patient voice in cell therapyhttps://pharmaphorum.com/market-access-2/lymphoma-action-championing-the-patient-voice-in-cell-therapy/
Heat Bio’s shares ignite on Opdivo combination data in NSCLCThe pairing of Heat Biologics’ lead drug HS-110 with Bristol-Myers Squibb’s blockbuster checkpoint inhibitor Opdivo has boosted survival Share XHeat Bio’s shares ignite on Opdivo combination data in NSCLChttps://pharmaphorum.com/news/heat-bios-shares-ignite-on-opdivo-combination-data-in-nsclc/
BMS finally gets FDA OK for liso-cel, sets $410k launch priceBristol-Myers Squibb finally has FDA approval for its CAR-T therapy liso-cel, which has been cleared by the US Share XBMS finally gets FDA OK for liso-cel, sets $410k launch pricehttps://pharmaphorum.com/news/bms-finally-gets-fda-ok-for-liso-cel-sets-410k-launch-price/
Gene editing: beyond the hypeGenome editing is an exciting but still nascent field, and companies in the area face as many obstacles Share XGene editing: beyond the hypehttps://pharmaphorum.com/r-d/views-analysis-r-d/genome-editing-sangamo-beyond-the-hype/
Oxford BioTherapeutics to research cell therapies for Gilead’s KiteGilead Sciences’ Kite unit has teamed up with the UK’s Oxford BioTherapeutics (OBT) to develop a new clutch Share XOxford BioTherapeutics to research cell therapies for Gilead’s Kitehttps://pharmaphorum.com/news/oxford-biotherapeutics-to-research-cell-therapies-for-gileads-kite/
Why cell therapy manufacture is a team sportLouis van de Wiel, Vice President, Site Head EU Manufacturing, Kite, a Gilead Company, reveals the complexity that Share XWhy cell therapy manufacture is a team sporthttps://pharmaphorum.com/market-access-2/why-cell-therapy-manufacture-is-a-team-sport/